Cargando…

Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice

BACKGROUND: Mice with functional ablation of the neurokinin-1 receptor gene (NK1R(−/−)) display behavioural abnormalities which resemble the hyperactivity, inattention and impulsivity seen in Attention Deficit Hyperactivity Disorder (ADHD). Here, we investigated whether the established ADHD treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pillidge, Katharine, Porter, Ashley J., Vasili, Temis, Heal, David J., Stanford, S. Clare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258612/ https://www.ncbi.nlm.nih.gov/pubmed/25450119 http://dx.doi.org/10.1016/j.pbb.2014.10.008

Ejemplares similares

The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene ‘knockout’ mice: Sex differences and implications for the treatment of attention deficit hyperactivity disorder
por: Porter, Ashley J., et al.
Publicado: (2015)

Perseveration by NK1R-/- (‘knockout’) mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test
por: Pillidge, Katharine, et al.
Publicado: (2016)

The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder
por: Pillidge, Katharine, et al.
Publicado: (2016)

Differences in the performance of NK1R−/− (‘knockout’) and wildtype mice in the 5‑Choice Continuous Performance Test
por: Porter, Ashley J., et al.
Publicado: (2016)

The behavioural response of mice lacking NK(1) receptors to guanfacine resembles its clinical profile in treatment of ADHD
por: Pillidge, Katharine, et al.
Publicado: (2014)

Hyperactive and impulsive behaviors of LMTK1 knockout mice
por: Takahashi, Miyuki, et al.
Publicado: (2020)

Targeting impulsivity in Parkinson’s disease using atomoxetine
por: Kehagia, Angie A., et al.
Publicado: (2014)

Effect of Atomoxetine on Hyperactivity in an Animal Model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Moon, Su Jin, et al.
Publicado: (2014)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Capsaicin-Mediated Neurogenic Vasodilatation in Neurokinin-1, NK(1), Receptor Knockout Mice
por: Grant, A. D., et al.
Publicado: (2001)

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
por: Hammerness, Paul, et al.
Publicado: (2009)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia
por: Sumner, Calvin R, et al.
Publicado: (2009)

Efficacy and Safety of Atomoxetine in the Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder
por: Kohn, Michael R., et al.
Publicado: (2012)

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Kabul, Samaneh, et al.
Publicado: (2015)

Atomoxetine-Associated Eyebrow Alopecia in a Girl With Attention-Deficit/Hyperactivity Disorder
por: Zhang, Ying, et al.
Publicado: (2021)

Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder
por: Nagai, Tsutomu, et al.
Publicado: (2022)

A lack of functional NK1 receptors explains most, but not all, abnormal behaviours of NK1R-/- mice1
por: Porter, A J, et al.
Publicado: (2015)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
por: Upadhyaya, Himanshu P., et al.
Publicado: (2013)

Successful Treatment with Atomoxetine of an Adolescent Boy with Attention Deficit/Hyperactivity Disorder, Extreme Obesity, and Reduced Melanocortin 4 Receptor Function
por: Pott, Wilfried, et al.
Publicado: (2013)

Effects of Atomoxetine on Motor and Cognitive Behaviors and Brain Electrophysiological Activity of Dopamine Transporter Knockout Rats
por: Ptukha, Maria, et al.
Publicado: (2022)

Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis
por: Faraone, Stephen V, et al.
Publicado: (2005)

Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder
por: Garg, Jasmin, et al.
Publicado: (2015)

Atomoxetine Induced Hypomania in a Patient with Bipolar Disorder and Adult Attention Deficit Hyperactivity Disorder
por: Kumar, Vijaya, et al.
Publicado: (2017)

Systematic Review of Suicidal Behaviors Related to Methylphenidate and Atomoxetine in Patients With Attention Deficit Hyperactivity Disorder
por: Kim, Jae Heon, et al.
Publicado: (2023)

Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research
por: Higgins, Guy A., et al.
Publicado: (2020)

A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder
por: Carlson, Gabrielle A, et al.
Publicado: (2007)

Advanced Test of Attention in Children with Attention-Deficit/Hyperactivity Disorder in Japan for Evaluation of Methylphenidate and Atomoxetine Effects
por: Fujioka, Toru, et al.
Publicado: (2016)

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine
por: Joseph, Alain, et al.
Publicado: (2016)

Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder
por: Clemow, David B., et al.
Publicado: (2016)

Clinical effects of repetitive transcranial magnetic stimulation combined with atomoxetine in the treatment of attention-deficit hyperactivity disorder
por: Cao, Pengfei, et al.
Publicado: (2018)

Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study
por: Ruppert, Katrin, et al.
Publicado: (2022)

IL1RAPL1 knockout mice show spine density decrease, learning deficiency, hyperactivity and reduced anxiety-like behaviours
por: Yasumura, Misato, et al.
Publicado: (2014)

ADHD-hyperactive/impulsive subtype in adults
por: Gibbins, Christopher, et al.
Publicado: (2010)

Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians
por: Bushe, Chris J., et al.
Publicado: (2011)

Structural insights into the activation of neurokinin 2 receptor by neurokinin A
por: Sun, Wenjing, et al.
Publicado: (2022)

Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials
por: Wehmeier, Peter M, et al.
Publicado: (2010)

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain
por: Hong, Jihyung, et al.
Publicado: (2009)

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
por: Clemow, David B, et al.
Publicado: (2017)

Differential therapeutic effects of atomoxetine and methylphenidate in childhood attention deficit/hyperactivity disorder as measured by near-infrared spectroscopy
por: Nakanishi, Yoko, et al.
Publicado: (2017)

Clinical and Neuropsychological Factors Associated with Treatment Response and Adverse Events of Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder
por: Park, Kee Jeong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4llde3gg9cni4mtn6p1sfqaol0